FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical industry and represents a pharmaceutical composition for treating non-alcoholic fatty liver disease, which is obtained from the following medicinal raw materials: from 26.25 g to 180 g of silybin, from 45 g to 195 g of phospholipid, from 75 g to 600 g of water extract from Puer tea leaves, from 18.75 g to 120 g of vitamin E or vitamin E acetate or vitamin E succinate, from 25 g to 180 g of L-carnitine or L-carnitine tartrate.
EFFECT: invention provides an excellent dissolution rate in vitro, bioavailability and therapeutic effectiveness.
20 cl, 2 ex, 6 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE | 2016 |
|
RU2699011C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND RADIX PUERARIAE EXTRACT | 2016 |
|
RU2697670C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VITAMIN E | 2016 |
|
RU2695806C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN | 2016 |
|
RU2697523C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SILYBIN | 2016 |
|
RU2695224C2 |
| BIOCOMPOSITION POSSESSING ANTITOXIC AND ANTI-ADAPTOSIS EFFECT, PROPHYLACTIC BIOLOGICAL SUPPLEMENT BASED ON THEREOF | 2005 |
|
RU2319498C2 |
| APPLICATION OF EXTRACTS OF GINSENG, GYNSENOSIDES AND DERIVATIVES OF GINSENOSIDE FOR THE PREPARATION OF MEDICAL PRODUCTS OR REMEDIES FOR THE TREATMENT OF DISORDERS CAUSED BY CMV | 2016 |
|
RU2679903C1 |
| COMPOSITIONS OF GINSENOSIDE RG3 AND GINSENOSIDE RG5 AND THEIR PHARMACEUTICAL USES, INCLUDING ANTITUMOR EFFECTS | 2021 |
|
RU2812611C1 |
| COMPOSITION FOR PREVENTING OR TREATING OBESITY CONTAINING A-LIPOIC ACID AND N-ACETYLCYSTEINE AS ACTIVE INGREDIENTS | 2015 |
|
RU2670612C9 |
| THERAPEUTIC HERBAL EXTRACT HAVING ACTION ON OBESITY | 2008 |
|
RU2475256C2 |
